Related Experiment Video

Updated: Jul 11, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K

[New aspects in pediatric pulmonary hypertension - Commented 2022ERS/ESC-PH guidelines]

Christian Apitz1, Rainer Kozlik-Feldmann2, Christina A Eichstaedt3

  • 1Universitätsklinik für Kinder- und Jugendmedizin Ulm, Sektion Pädiatrische Kardiologie, Ulm, Deutschland.

Pneumologie (Stuttgart, Germany)
|November 14, 2023
PubMed

Insights

Pediatric pulmonary hypertension (PH) has unique causes like congenital heart disease and genetic factors, differing from adult PH. Treatment requires specialized diagnostic and therapeutic approaches for children.

Area of Science:

  • Pediatric pulmonology
  • Cardiology
  • Genetics

Context:

  • Childhood pulmonary hypertension (PH) presents distinct pathophysiological features compared to adult PH.
  • Congenital heart disease-associated pulmonary arterial hypertension is a key differentiator in pediatric cases.
  • Developmental lung diseases and genetic/syndromal abnormalities are frequently associated with pediatric PH.

Purpose:

  • To highlight the unique aspects of pediatric pulmonary hypertension (PH).
  • To emphasize the need for modified diagnostic algorithms and targeted therapeutic strategies in children.
  • To discuss the specific features of pediatric PH as presented in the 2022 ERS/ESC-PH guidelines.

Summary:

  • Pediatric PH differs from adult PH due to unique pathophysiology, including congenital heart disease, developmental lung issues, and genetic abnormalities.
  • Effective treatment necessitates a diagnostic algorithm adapted for children and therapies addressing specific pathophysiological mechanisms.
  • The 2022 European Respiratory Society/European Society of Cardiology (ERS/ESC) guidelines dedicate a chapter to pediatric PH, with expert commentary provided.

Impact:

  • Informs clinical practice for diagnosing and managing pediatric pulmonary hypertension.
  • Guides the development of tailored treatment strategies for children with PH.
  • Enhances understanding of the specific challenges and considerations in childhood PH.

More Related Videos

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

85
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

987

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
194
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
233